Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02460731 · ClinicalTrials.gov registry record · Phase 1

Young Plasma Transfusions for Progressive Supranuclear Palsy

A Phase 1 study of Progressive Supranuclear Palsy, sponsored by University of California, San Francisco.

Completed
Registry status
Phase 1
Development phase
6
Enrollment target
1
Study location

NCT02460731: Completed Phase 1 study of Progressive Supranuclear Palsy, sponsored by University of California, San Francisco.

NCT02460731 is a Phase 1 study of Progressive Supranuclear Palsy that has completed, run by University of California, San Francisco. The registered enrollment target is 6 participants, below the 452-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02460731, a Phase 1 study of Progressive Supranuclear Palsy, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
Phase 1
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

This is a phase 1, multi-center, open-label study of the safety, tolerability, pharmacodynamics, and preliminary efficacy of young (\<30 years of age) healthy male donor plasma transfusions in patients with PSP. Up to 10 subjects will receive once monthly 4-unit transfusions of young healthy male donor plasma for 6 months.

Primary Outcome

To determine the safety and tolerability of once monthly 4-unit transfusions of young (\<30 years of age) healthy male donor plasma for 6 months in patients with progressive supranuclear palsy (PSP). Number of patients experiencing drug limiting toxicity (DLT), defined as: 1) any Grade 3 or higher adverse event (AE) per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) for which there is reasonable possibility that salsalate caused the event, 2) any Grade 2 A

Conditions Studied

Progressive Supranuclear Palsy

Interventions

  • BIOLOGICAL Fresh Frozen Plasma

Study Locations (1)

California

  • University of California, San Francisco, Memory and Aging Center - San Francisco

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2015-05
Est. Completion 2019-12
Phase Phase 1
University of California, San Francisco

1,713 total trials

What the finished NCT02460731 record still lists

NCT02460731 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 452-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Progressive Supranuclear Palsy appearing as the primary indexed condition, and to 1 intervention - of which Fresh Frozen Plasma is the first listed.

NCT02460731 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02460731 about?

NCT02460731 is a clinical study titled "Young Plasma Transfusions for Progressive Supranuclear Palsy". This is a phase 1, multi-center, open-label study of the safety, tolerability, pharmacodynamics, and preliminary efficacy of young (\<30 years of age) healthy male donor plasma transfusions in patients with PSP. Up to 10 subjects will receive once monthly 4-unit transfusions of young healthy male do...

What is the current status of trial NCT02460731?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2015-05. Estimated completion is 2019-12.

What conditions does trial NCT02460731 study?

This clinical trial studies the following conditions: Progressive Supranuclear Palsy.

What interventions are being tested in trial NCT02460731?

The interventions under investigation include: Fresh Frozen Plasma (BIOLOGICAL).

Who is sponsoring clinical trial NCT02460731?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02460731 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Progressive Supranuclear Palsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02460731's enrollment target sits among peer trials

6 19th of 18 the lowest of 18 other Progressive Supranuclear Palsy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Progressive Supranuclear Palsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02460731, the US trial registry maintained by the National Library of Medicine. NCT02460731 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.